Table 1 Characteristics of patients undergoing hemipelvic replacement surgery

Number

32

19

13

Demographic

 Sex*

0.62

  Male

18 (56.2)

10 (52.6)

8 (61.5)

  Female

14 (43.8)

7 (36.8)

7 (53.8)

 Age†(yr)

45.0 ± 13.4

46.3 ± 11.5

43.0 ± 16.0

 BMI† (kg/m²)

24.4 ± 3.1

24.9 ± 2.9

23.8 ± 3.3

 Follow-up time† (mo)

41.6 ± 10.5

42.3 ± 12.0

40.5 ± 8.0

Tumor histology*

0.47

 Chondrosarcoma

12 (37.5)

7 (36.8)

5 (38.5)

 Osteosarcoma

7 (21.9)

4 (21.1)

3 (23.1)

 Ewing sarcoma

6 (18.8)

3 (15.8)

3 (23.1)

 Solitary plasmacytoma

2 (6.3)

2 (10.5)

 Synovial sarcoma

2 (6.3)

2 (10.5)

 Spindle cell carcinomas

1 (3.1)

1 (5.3)

 Myofibroblastic sarcoma

1 (3.1)

1 (7.7)

 Solitary fibrous tumor

1 (3.1)

1 (7.7)

Tumor volume

 (Length × Width × Height, cm)

 Tumor length†(cm)

9.7 ± 1.6

10.1 ± 2.6

9.1 ± 1.6

 Tumor width†(cm)

6.9 ± 1.2

6.9 ± 1.3

6.7 ± 1.2

 Tumor height†(cm)

5.2 ± 1.2

5.6 ± 1.3

4.8 ± 1.1

Preoperative staging*

0.13

 IIB

27 (90.6)

16 (84.2)

11 (84.6)

 III

5 (9.4)

3 (15.9)

2 (15.4)

Neoadjuvant chemotherapy

 No. of patients*

14 (4.8)

8 (42.1)

6 (46.2)

Enneking Reconstruction Classification*

0.87

 Type I + II

8 (25.0)

5 (26.3)

3 (23.1)

 Type II + III

11 (34.4)

7 (36.8)

4 (30.8)

 Type I + II + III

13 (40.6)

7 (36.8)

6 (46.2)

Preoperative MSTS Score

15.0 ± 2.4

15.5 ± 2.5

14.3 ± 2.0

Preoperative HHS Score

63.5 ± 6.6

64.1 ± 7.5

62.7 ± 5.3